| Autor: |
Borstnar Simona, Bozovic-Spasojevic Ivana, Cvetanovic Ana, Plavetic Natalija Dedic, Konsoulova Assia, Matos Erika, Popovic Lazar, Popovska Savelina, Tomic Snjezana, Vrdoljak Eduard |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Radiology and Oncology, Vol 58, Iss 2, Pp 258-267 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1581-3207 |
| DOI: |
10.2478/raon-2024-0030 |
| Popis: |
Recent evidence brought by novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates is leading to significant changes in HER2-negative breast cancer (BC) best practices. A new targetable category termed ‘HER2-low’ has been identified in tumors previously classified as ‘HER2-negative’. Daily practice in pathology and medical oncology is expected to align to current recommendations, but patient access to novel anticancer drugs across geographies might be impeded due to local challenges. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
